Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

Published:2018-06-20 Issue:8 Volume:93 Page:985-993
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Leleu Xavier¹^ORCID,Masszi Tamas²,Bahlis Nizar J.³,Viterbo Luisa⁴,Baker Bartrum⁵,Gimsing Peter⁶,Maisnar Vladimir⁷,Samoilova Olga⁸,Rosiñol Laura⁹,Langer Christian¹⁰,Song Kevin¹¹,Izumi Tohru¹²,Cleeland Charles¹³,Berg Deborah¹⁴,Lin Huamao Mark¹⁴,Zhu Yanyan¹⁴,Skacel Tomas¹⁴¹⁵,Moreau Philippe¹⁶^ORCID,Richardson Paul G.¹⁷

Affiliation:

1. Department of Haematology; Hospital La Milétrie, and INSERM CIC 1402; Poitiers France

2. Department of Hematology and Stem Cell Transplantation, St. István and St. László Hospital, 3rd Department of Internal Medicine; Semmelweis University; Budapest Hungary

3. Southern Alberta Cancer Research Institute, University of Calgary; Calgary Alberta Canada

4. Serviço de Onco-Hematologia, Instituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial (IPOPFG, EPE); Porto Portugal

5. Department of Haematology; Palmerston North Hospital; Palmerston North Manawatu New Zealand

6. Department of Hematology; University Hospital Rigshospitalet; Copenhagen Denmark

7. 4 Department of Medicine - Hematology; University Hospital; Hradec Kralove Czech Republic

8. Nizhnii Novgorod Region Clinical Hospital; Nizhnii Novgorod Russia

9. Department of Hematology; University of Barcelona; Barcelona Spain

10. Department of Internal Medicine III; University Hospital of Ulm; Ulm Germany

11. Division of Hematology; University of British Columbia; Vancouver Canada

12. Department of Hematology; Tochigi Cancer Center, Utsunomiya; Tochigi Japan

13. Department of Symptom Research; University of Texas M.D. Anderson Cancer Center; Houston Texas

14. Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

15. Department of Hematology; Charles University General Hospital; Prague Czech Republic

16. Department of Hematology; University Hospital Hôtel Dieu; Nantes France

17. Department of Hematologic Oncology; Dana-Farber Cancer Institute; Boston Massachusetts

Funder

Museums Association

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25134/fullpdf

Reference42 articles.

1. 2015

2. 2016 https://www.takeda.com/news/2016/20160916_7564.html

3. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma;Moreau;N Engl J Med.,2016

4. National Cancer Institute 2017 https://seer.cancer.gov/statfacts/html/mulmy.html

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience;Cancer Medicine;2024-04

2. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma;New England Journal of Medicine;2023-09-14

3. Assessment tools for patient-reported outcomes in multiple myeloma;Supportive Care in Cancer;2023-06-30

4. Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study;Annals of Hematology;2023-06-10

5. Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review;Clinical Lymphoma Myeloma and Leukemia;2023-06